BRIEF published on 10/28/2024 at 08:05, 2 years ago Ondine Biomedical fait progresser la commercialisation de Steriwave Ondine Biomedical Technologie Steriwave Résistance Aux Antimicrobiens Innovation Dans Le Domaine De La Santé Infections Associées Aux Soins De Santé
BRIEF published on 10/28/2024 at 08:05, 2 years ago Ondine Biomedical Advances Steriwave Commercialization Antimicrobial Resistance Ondine Biomedical Steriwave Technology Healthcare-associated Infections Innovation In Healthcare
PRESS RELEASE published on 10/28/2024 at 08:00, 2 years ago Ondine Continues Commercial Growth Ondine Biomedical Inc. provides updates on the commercial roll-out of its Steriwave® nasal decolonization technology, reducing healthcare-associated infections with light-activated treatment Ondine Biomedical Inc. Nasal Decolonization Steriwave Healthcare-associated Infections Antimicrobial Treatments
BRIEF published on 10/23/2024 at 08:05, 2 years ago Ondine Biomedical Inc. lance le projet pilote Steriwave au King's College Hospital Steriwave Ondine Biomedical Innovation Dans Le Domaine De La Santé Hôpital King's College Traitement Antimicrobien
BRIEF published on 10/23/2024 at 08:05, 2 years ago Ondine Biomedical Inc. Launches Steriwave Pilot at King's College Hospital Steriwave Healthcare Innovation Ondine Biomedical Antimicrobial Treatment King's College Hospital
PRESS RELEASE published on 10/23/2024 at 08:00, 2 years ago Ondine Biomedical Inc. Announces King's College Hospital to Run Steriwave Pilot Ondine Biomedical Inc. collaborates with King's College Hospital to pilot Steriwave® light-activated antimicrobial tech for preventing HAIs. Steriwave rapidly eliminates pathogens without resistance Ondine Biomedical Inc. Steriwave Hospital-acquired Infections Antimicrobial Technology King's College Hospital
BRIEF published on 09/30/2024 at 11:10, 2 years 1 month ago Ondine Biomedical Reports Robust Growth in H1 2024 Clinical Trials Steriwave Ondine Biomedical Financial Growth Hospital Adoption
BRIEF published on 09/30/2024 at 11:10, 2 years 1 month ago Ondine Biomedical annonce une croissance robuste au premier semestre 2024 Croissance Financière Steriwave Ondine Biomedical Essais Cliniques Adoption À L'hôpital
PRESS RELEASE published on 09/30/2024 at 11:05, 2 years 1 month ago Ondine Biomedical Reports Robust Growth in H1 2024 Ondine Biomedical Inc. reports unaudited operational and financial results for the first half of 2024, showing strong revenue growth and strategic partnerships Financial Performance Ondine Biomedical Inc. Strategic Partnership Clinical Trials Operational Results
BRIEF published on 09/30/2024 at 08:05, 2 years 1 month ago Ondine Biomedical annonce une croissance robuste au premier semestre 2024 Résultats Financiers Ondine Biomedical Essais Cliniques Steriwave® Premier Semestre 2024
Published on 11/13/2026 at 17:25, 26 minutes ago Sekur Private Data Raises SekurOne Price 25% to US$3,750 Per Year
Published on 11/13/2026 at 15:40, 2 hours 11 minutes ago Vulcan Minerals Inc. - Review and Update on Affiliated Company Atlas Salt Inc.
Published on 11/13/2026 at 15:30, 2 hours 21 minutes ago Road Access Completed Drill Program to Begin
Published on 11/13/2026 at 15:05, 2 hours 46 minutes ago ACCESS Newswire Continues to Repurchase its Shares
Published on 11/13/2026 at 15:00, 2 hours 51 minutes ago Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates
Published on 11/13/2026 at 16:15, 1 hour 36 minutes ago REPLOID explores potential for Austrian farmers and foresters to save hundreds of millions of euros annually in mineral oil tax with locally produced biodiesel from insect fat
Published on 11/13/2026 at 11:35, 6 hours 16 minutes ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 6 hours 16 minutes ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 9 hours 51 minutes ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 18 hours 38 minutes ago Belgrano continues the implementation of its public share buyback offer (OPRA)
